Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin's AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the.

29.04.2026

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass.

27.04.2026

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III TULIP-SC trial, which showed that subcutaneous (SC) administration of SAPHNELO led to a statistically significant and.

20.04.2026

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. I.

AstraZeneca PLC (AZN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AstraZeneca PLC (AZN)

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Search stocks

AstraZeneca PLC (AZN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AstraZeneca PLC (AZN)

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD